Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 4, Issue 7, 2009, Pages 787-791

  Solomon, Benjamin ^a   Pearson, Richard B ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

AKT; MTOR; NSCLC; Phosphatidylinositol 3 kinase

Indexed keywords

ANTINEOPLASTIC AGENT; BGT 226; BRX 235; ISOENZYME; LY 2994002; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE 1A; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN P110; PX 866; SF 1126; UNCLASSIFIED DRUG; XL 147; XL 765;

CANCER GENETICS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME SUBUNIT; FEEDBACK SYSTEM; GENE INACTIVATION; GENE MUTATION; HUMAN; LUNG SMALL CELL CANCER; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION;

EID: 68549098158     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a74dba     Document Type: Article

References (93)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70. (Pubitemid 30046295)
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-619. (Pubitemid 44100518)
3. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-573. (Pubitemid 40799249)
4. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005;102:802-807. (Pubitemid 40282746)
5. Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associatedPIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005;65:10992-11000.
6. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A 2006;103:1475-1479. (Pubitemid 43191190)
7. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A 2005;102:18443-18448. (Pubitemid 43011245)
8. Gaidarov I, Smith ME, Domin J, Keen JH. The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol Cell 2001;7:443-449. (Pubitemid 32206511)
9. Nobukuni T, Kozma SC, Thomas G. Hvps34, an ancient player, enters a growing game: mTOR Complex1/S6K1 signaling. Curr Opin Cell Biol 2007;19:135-141. (Pubitemid 46386413)
10. Gulati P, Gaspers LD, Dann SG, et al. Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab 2008;7: 456-465. (Pubitemid 351598024)
11. Foukas LC, Claret M, Pearce W, et al. Critical role for the p110[alpha] phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006;441:366-370. (Pubitemid 44050203)
12. Knight ZA, Gonzalez B, Feldman ME, et al. A Pharmacological Map of the PI3-K Family Defines a Role for p110[alpha] in Insulin Signaling. Cell 2006;125:733-747.
13. Yuan TL, Choi HS, Matsui A, et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci U S A 2008;105:9739-9744. (Pubitemid 352031370)
14. Samuels Y, Wang Z, Bardelli A, et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers. Science 2004;304:554. (Pubitemid 38541907)
15. Campbell IG, Russell SE, Choong DYH, et al. Mutation of the PIK3CA Gene in Ovarian and Breast Cancer. Cancer Res 2004;64:7678-7681. (Pubitemid 39446895)
16. Guillermet-Guibert J, Bjorklof K, Salpekar A, et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G proteincoupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 2008;105:8292-8297. (Pubitemid 351904749)
17. Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110[bgr] in cell growth, metabolism and tumorigenesis. Nature 2008;454:776-779.
18. Philp AJ, Campbell IG, Leet C, et al. The Phosphatidylinositol 3'-kinase p85{alpha} Gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426-7429. (Pubitemid 32995029)
19. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-1812.
20. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068.
21. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol- 3-OH kinase as a direct target of Ras. Nature 1994;370:527-532. (Pubitemid 24264918)
22. Gupta S, Ramjaun AR, Haiko P, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007;129:957-968. (Pubitemid 46802703)
23. Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008;27:5477-5485.
24. Bellacosa A, Chan TO, Ahmed NN, et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998;17:313-325. (Pubitemid 28383008)
25. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307: 1098-1101.
26. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-1274.
27. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005;18:13-24. (Pubitemid 40444644)
28. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
29. Sun SY, Fu H, Khuri FR. Targeting mTOR signaling for lung cancer therapy. J Thorac Oncol 2006;1:109-111. (Pubitemid 47163996)
30. Pearce LR, Huang X, Boudeau J, et al. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 2007;405: 513-522. (Pubitemid 47172049)
31. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484. (Pubitemid 43199434)
32. Haar EV, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007;9:316-323. (Pubitemid 46344611)
33. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6:91-99. (Pubitemid 38903165)
34. Sofer A, Lei K, Johannessen CM, Ellisen LW. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol 2005;25:5834-5845. (Pubitemid 40946541)
35. Hannan KM, Brandenburger Y, Jenkins A, et al. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol 2003;23:8862-8877. (Pubitemid 37433385)
36. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006; 25:6436-6446.
37. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008;27:5527-5541.
38. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-1356.
39. Vivanco I, Palaskas N, Tran C, et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 2007;11:555-569. (Pubitemid 46856910)
40. Hezel AF, Bardeesy N. LKB1; linking cell structure and tumor suppression. Oncogene 2008;27:6908-6919.
41. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-3074.
42. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053-2059. (Pubitemid 39534841)
43. Cappuzzo F, Ligorio C, Janne PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridizationpositive/ phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007; 25:2248-2255. (Pubitemid 46954651)
44. Tsurutani J, Fukuoka J, Tsurutani H, et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 2006;24:306-314. (Pubitemid 46622059)
45. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008;27:5486-5496.
46. Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 2006; 1:629-634. (Pubitemid 47163949)
47. Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006;54:209-215. (Pubitemid 44764916)
48. Okudela K, Suzuki M, Kageyama S, et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007;57:664-671. (Pubitemid 47353042)
49. Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68:6913-6921.
50. Kawano O, Sasaki H, Okuda K, et al. PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer 2007;58:159-160. (Pubitemid 47379973)
51. Angulo B, Suarez-Gauthier A, Lopez-Rios F, et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008;214:347-356. (Pubitemid 351212390)
52. Forgacs E, Biesterveld EJ, Sekido Y, et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998;17:1557-1565. (Pubitemid 28472760)
53. Kohno T, Takahashi M, Manda R, Yokota J. Inactivation of the PTEN/ MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 1998;22:152-156. (Pubitemid 28208808)
54. Yokomizo A, Tindall DJ, Drabkin H, et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 1998;17:475-479. (Pubitemid 28395912)
55. Marsit CJ, Zheng S, Aldape K, et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Human Pathology 2005;36:768-776. (Pubitemid 41112032)
56. Soria J-C, Lee H-Y, Lee JI, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002;8:1178-1184.
57. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in thepleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-444. (Pubitemid 47123510)
58. Do H, Solomon B, Mitchell PL, Fox SB, Dobrovic A. Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes 2008;1:14.
59. Malanga D, Scrima M, De Marco C, et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008;7:665-669.
60. Bleeker FE, Felicioni L, Buttitta F, et al. AKT1(E17K) in human solid tumours. Oncogene. 2008;27:5648-5650.
61. Sanchez-Cespedes M, Parrella P, Esteller M, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002;62:3659-3662. (Pubitemid 34728843)
62. Carretero J, Medina PP, Pio R, Montuenga LM, Sanchez-Cespedes M. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene 2004;23:4037-4040. (Pubitemid 38747933)
63. Matsumoto S, Iwakawa R, Takahashi K, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007;26:5911-5918.
64. Koivunen JP, Kim J, Lee J, et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer 2008;99:245-252.
65. Zhong D, Guo L, de Aguirre I, et al. LKB1 mutation in large cell carcinoma of the lung. Lung Cancer 2006;53:285-294. (Pubitemid 44189563)
66. Onozato R, Kosaka T, Achiwa H, et al. LKB1 gene mutations in Japanese lung cancer patients. Cancer Sci 2007;98:1747-1751. (Pubitemid 47487911)
67. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448:807-810. (Pubitemid 47266337)
68. Izzard RA, Jackson SP, Smith GCM. Competitive and Noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res 1999;59: 2581-2586. (Pubitemid 29269102)
69. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 2007;404:15-21.
70. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008;27:5511-5526.
71. Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 2009;8:1-9.
72. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-1508. (Pubitemid 43259931)
73. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-1610.
74. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008;5:e8. (Pubitemid 351198268)
75. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004;166:213-223. (Pubitemid 38988774)
76. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9: 341-349.
77. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-8030.
78. Legrier ME, Yang CP, Yan HG, et al. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 2007;67:11300-11308.
79. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al. Targeting AKT/ mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008;118:3051-3064.
80. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346. (Pubitemid 40425952)
81. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 2008;26:4268-4275.
82. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
83. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655. (Pubitemid 40812628)
84. Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008;99:2280-2285.
85. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006;66:283-289. (Pubitemid 43166034)
86. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104: 20932-20937.
87. Kubo T, Yamamoto H, Lockwood WW, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 2009;124:1778-1784.
88. Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009;20:298-304.
89. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008;68:4971-4976.
90. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-17.
91. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283.
92. Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008;10:298-302. (Pubitemid 351328588)
93. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-566. (Pubitemid 47206930)